Lamivir-S is manufactured by Cipla Pharmaceuticals Limited. Each tablet contains 30mg of Stavudine and 150 mg of Lamivudine. Lamivir-S is indicated for the treatment of HIV infection as a component of combination antiretroviral therapy. The interval between doses of Lamivir S should be 12 hours. Lamivir S may be taken with or without food. People who have clinically significant hypersensitivity (anaphylaxis) to any of the components that are in the formulation must not take Lamivir-S. Due to the fact that it is a fixed-dose combination, Lamivir-S must not be recommended for patients requiring dosage adjustment, such as those with reduced renal function (creatinine clearance ≤ 50 ml/min), or those experiencing dose-limiting adverse events. Dosage is 1 tablet twice a day for patients weighing less than 60 kg.